DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the market capitalisation of Aptus Pharma Ltd?

Aptus Pharma Ltd has a market capitalisation of approximately ₹377 crore.

Aptus Pharma Ltd

APTUSPHARMALTD·NSE·Consumer Goods

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Consumer Goods · Household Appliances

High-quality returns — 31% on equity

52W₹32

₹239-16%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹377 Cr

P/E Ratio

N/A

P/B Ratio

18.86

EPS

₹2.48

Book Value

₹11.65

ROE

30.50%Strong

ROCE

38.20%Efficient

Dividend Yield

0.00%

Debt / Equity

0.31Moderate

Face Value

₹10.00

52W High

₹238.80

52W Low

₹32.32

Sector

Consumer Goods

Industry

Household Appliances

Fairly Valued

Narrow moatHigh uncertainty

Fair value estimate

₹40

No recent traded price

BearFair valueBull

₹27₹40₹45

/100

Business quality — Solid

Growth 50Profitability 80Efficiency 100Valuation 85

Plain English

Our view

High-quality returns — 31% on equity
Low debt relative to equity

Strengths

Low debt relative to equity
Strong returns on equity (31%)
Capital is working hard (ROCE 38%)
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

45% ROE fading to 13% over ~10 yrs, on ₹12 book

₹43

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹27

Analyst target

No analyst coverage

—

Blended fair value₹40

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (31%)
Capital is working hard (ROCE 38%)
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

30.5%Strong

Above 15% is considered healthy for Indian equities

ROCE

38.2%Efficient

Above 18% means capital is working hard

Debt/Eq

0.31Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹377 Cr

P/B

18.86

EPS

₹2.48

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

Strong

+50% rev CAGR

Profitability

Excellent

30.5% ROE

Financial health

Comfortable

D/E 0.31

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+49.6%

—

10Y

—

Profit

+189.3%

—

10Y

—

EPS

+4.2%

—

10Y

—

Profile

Pros

Company has reduced debt.
Company has a good return on equity (ROE) track record: 3 Years ROE 40.8%

Watch-outs

Cons

Stock is trading at 16.5 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Debtor days have increased from 99.8 to 147 days.
Working capital days have increased from 73.4 days to 117 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 May 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

73%

Promoter

Promoters

72.9%0.00

Public

23.8%+0.29

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

3.4%

Total shareholders

356+19 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter72.89%

Public23.76%

Others3.35%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations.[1]

Aptus Pharma Ltd valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

Aptus Pharma Ltd peers in Consumer Goods

Other Consumer Goods stocks on the NSE & BSE. See the full Consumer Goods sector list.

Aptus Pharma Ltd

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

Aptus Pharma Ltd valuation & research

Aptus Pharma Ltd peers in Consumer Goods

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions